Contemporary Questions in Pulmonary and Critical Care Infections-Fungal therapeutics Johnson

Fungal therapeutics Johnson

Pdf Summary

The presentation by Dr. Melissa D. Johnson from Duke University explores the current and future landscape of antifungal therapeutics, especially in treating pulmonary and critical care infections. Dr. Johnson, with disclosed financial ties to several pharmaceutical entities, discusses both approved and investigational antifungal agents. Key topics include the characteristics, mechanisms, and potential roles of existing and emerging antifungals. <br /><br />Current antifungal agents such as Voriconazole and Amphotericin B, along with newer treatments like Isavuconazole, Rezafungin, and Ibrexafungerp, are analyzed in terms of their spectrum, efficacy, and potential applications. Isavuconazole, in particular, is highlighted for its FDA approval to treat invasive aspergillosis and mucormycosis in pediatric patients as young as one year, showcasing its expanded usage. <br /><br />Rezafungin, a newly approved echinocandin, is noted for its weekly dosing and use in treating invasive candidiasis and candidemia. Clinical trials demonstrate its efficacy comparable to Caspofungin while offering a potentially simpler regimen.<br /><br />Ibrexafungerp, an FDA-approved oral antifungal for vulvovaginal candidiasis, demonstrates efficacy against resistant Candida, including C. auris. Despite some drug interactions and safety concerns in pregnancy, its ease of administration offers treatment versatility.<br /><br />Dr. Johnson also reviews investigational drugs like Opelconazole, Olorofim, and Fosmanogepix and their roles in treating difficult fungal infections. These emerging therapies showcase promising results, especially for refractory infections or in patients with limited treatment options.<br /><br />In summary, the session highlights a growing antifungal pipeline, with innovations in drug delivery methods and expanded clinical trial data driving future treatment paradigms. The discussion reflects a landscape focused on overcoming emerging fungal resistance and providing effective therapies for complex infections.

Keywords

antifungal therapeutics

pulmonary infections

critical care

Voriconazole

Amphotericin B

Isavuconazole

Rezafungin

Ibrexafungerp

emerging antifungals

fungal resistance